| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 03/12/2024 | 13:00 | GlobeNewswire Inc. | Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis | NASDAQ:ROIV | Roivant Sciences Ltd |
| 03/12/2024 | 13:00 | GlobeNewswire Inc. | Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis | NASDAQ:ROIV | Roivant Sciences Ltd |
| 12/11/2024 | 13:00 | GlobeNewswire Inc. | Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |
| 29/10/2024 | 21:35 | GlobeNewswire Inc. | Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 | NASDAQ:ROIV | Roivant Sciences Ltd |
| 28/10/2024 | 14:25 | GlobeNewswire Inc. | Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% | NASDAQ:ROIV | Roivant Sciences Ltd |
| 18/09/2024 | 13:30 | GlobeNewswire Inc. | Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% | NASDAQ:ROIV | Roivant Sciences Ltd |
| 10/09/2024 | 12:30 | GlobeNewswire Inc. | Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator | NASDAQ:ROIV | Roivant Sciences Ltd |
| 10/09/2024 | 12:30 | GlobeNewswire Inc. | Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress | NASDAQ:ROIV | Roivant Sciences Ltd |
| 09/09/2024 | 13:00 | GlobeNewswire Inc. | Roivant Provides Update on Graves’ Disease Development Program | NASDAQ:ROIV | Roivant Sciences Ltd |
| 08/08/2024 | 13:00 | GlobeNewswire Inc. | Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |
| 25/07/2024 | 22:05 | GlobeNewswire Inc. | Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024 | NASDAQ:ROIV | Roivant Sciences Ltd |
| 31/05/2024 | 03:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ROIV | Roivant Sciences Ltd |
| 30/05/2024 | 22:46 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ROIV | Roivant Sciences Ltd |
| 30/05/2024 | 13:45 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ROIV | Roivant Sciences Ltd |
| 30/05/2024 | 13:00 | GlobeNewswire Inc. | Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |
| 16/05/2024 | 22:05 | GlobeNewswire Inc. | Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 | NASDAQ:ROIV | Roivant Sciences Ltd |
| 02/04/2024 | 13:00 | GlobeNewswire Inc. | Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million | NASDAQ:ROIV | Roivant Sciences Ltd |
| 26/03/2024 | 23:22 | PR Newswire (US) | Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 | NASDAQ:ROIV | Roivant Sciences Ltd |
| 13/02/2024 | 13:00 | GlobeNewswire Inc. | Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |
| 30/01/2024 | 22:05 | GlobeNewswire Inc. | Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 | NASDAQ:ROIV | Roivant Sciences Ltd |
| 20/12/2023 | 22:30 | GlobeNewswire Inc. | Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease | NASDAQ:ROIV | Roivant Sciences Ltd |
| 14/12/2023 | 15:00 | GlobeNewswire Inc. | Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease | NASDAQ:ROIV | Roivant Sciences Ltd |
| 28/11/2023 | 13:00 | GlobeNewswire Inc. | Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential | NASDAQ:ROIV | Roivant Sciences Ltd |
| 27/11/2023 | 14:00 | GlobeNewswire Inc. | Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus | NASDAQ:ROIV | Roivant Sciences Ltd |
| 13/11/2023 | 13:00 | GlobeNewswire Inc. | Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |
| 10/11/2023 | 14:00 | GlobeNewswire Inc. | Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors | NASDAQ:ROIV | Roivant Sciences Ltd |
| 30/10/2023 | 22:30 | GlobeNewswire Inc. | Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 | NASDAQ:ROIV | Roivant Sciences Ltd |
| 23/10/2023 | 21:41 | Dow Jones News | Trending: Roche to Buy Telavant From Roivant and Pfizer | NASDAQ:ROIV | Roivant Sciences Ltd |
| 23/10/2023 | 13:18 | IH Market News | Monday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and more | NASDAQ:ROIV | Roivant Sciences Ltd |
| 23/10/2023 | 10:16 | Dow Jones News | Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- Update | NASDAQ:ROIV | Roivant Sciences Ltd |